

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 8. (Cancelled)

9. (Currently Amended) A method of inhibiting tumor cell growth in a mammal, comprising administering to said mammal a composition comprising a thrombospondin ~~compound~~ polypeptide and an inhibitor of DNA topoisomerase I enzyme activity, wherein said tumor cell is a colon tumor cell, wherein said thrombospondin polypeptide is thrombospondin-1 (TSP-1) or thrombospondin-2 (TSP-2) and said inhibitor of DNA topoisomerase I enzyme activity is a water soluble camptothecin compound, and wherein tumor growth is inhibited in the presence of said thrombospondin polypeptide and said water soluble camptothecin compound compared to in the absence of said thrombospondin polypeptide and said water soluble camptothecin compound.

10. – 11. (Cancelled)

12. (Currently Amended) The method of claim 9, wherein said thrombospondin ~~compound~~ polypeptide is thrombospondin-1.

13. (Currently Amended) The method of claim 9, wherein said thrombospondin ~~compound~~ polypeptide is thrombospondin-2.

14. (Currently Amended) The method of claim 11, wherein said water-soluble camptothecin compound is irinotecan (CPT-11).

15. (Currently Amended) The method of claim 11, wherein said water-soluble camptothecin compound is topotecan.

16. (Cancelled).

17. (Original) The method of claim 9, wherein said mammal is a human.
18. (Currently Amended) The method of claim 9, wherein said thrombospondin ~~compound~~ polypeptide is administered prior to said inhibitor of DNA topoisomerase I enzyme activity.
19. (Currently Amended) The method of claim 9, wherein said inhibitor of DNA topoisomerase I enzyme activity is administered prior to said thrombospondin ~~compound~~ polypeptide.
20. (Currently Amended) The method of claim 9, wherein said thrombospondin ~~compound~~ polypeptide and said inhibitor of DNA topoisomerase I enzyme activity are administered simultaneously.